30 results on '"Kumar, Bhushan"'
Search Results
2. Comparative study of calcipotriol (0.005%) ointment and tazarotene (0.05% and 0.1%) gel in the treatment of stable plaque psoriasis.
- Author
-
Kaur I, Dogra S, Jain R, and Kumar B
- Subjects
- Administration, Topical, Adolescent, Adult, Calcitriol administration & dosage, Female, Gels, Humans, Male, Ointments, Pilot Projects, Prospective Studies, Psoriasis pathology, Young Adult, Calcitriol analogs & derivatives, Dermatologic Agents administration & dosage, Nicotinic Acids administration & dosage, Psoriasis drug therapy
- Abstract
Background: Topical therapies are the first line of treatment for patients with stable plaque psoriasis affecting a limited body surface area. Though in use for more than a decade, we could not find any reports of studies directly comparing calcipotriol and tazarotene., Aim: To evaluate the comparative efficacy and tolerability of calcipotriol and tazarotene in the treatment of stable plaque psoriasis., Methods: This was a prospective, right-left side intra-individual parallel 8-week study using calcipotriol 0.005% ointment applied twice daily (right side) versus tazarotene (left side) randomized to either 0.05% (group I) or 0.1% gel (group II) once daily in two groups, each of 10 patients. Efficacy was determined by the assessment of target psoriatic lesions under evaluation by using the severity scale (0-3) of erythema, scaling, and infiltration (ESI score). Evaluation was done at baseline (0 week), 4 weeks, and 8 weeks of treatment. At the end of 8 weeks, patients with more than 75% reduction in ESI score were considered to have marked improvement; 51% to 75%, moderate improvement; 26% to 50%, minimal improvement; and less than 25%, non-responders., Results: Seventeen patients (9 in group I, 8 in group II) completed the study. In group I, reduction in ESI score was significantly more at both 4 and 8 weeks on sides treated with calcipotriol, producing moderate-to-marked improvement (P<0.05). In group II, improvement was comparable in lesions treated with either calcipotriol or tazarotene (0.1%) at the end of 4 and 8 weeks. Adverse effects noted were mild--in the form of burning, pruritus, and irritation--and were observed more often in the lesions treated with tazarotene as compared to those in the lesions treated with calcipotriol, but the difference was not statistically significant. However, none of the patients discontinued the therapy because of adverse events., Conclusion: Topical calcipotriol 0.005% ointment is more effective than tazarotene 0.05% gel; however, its efficacy is comparable to tazarotene 0.1% gel in the treatment of stable plaque psoriasis.
- Published
- 2008
- Full Text
- View/download PDF
3. A randomized, double-blind, vehicle-controlled study of a novel liposomal dithranol formulation in psoriasis.
- Author
-
Saraswat A, Agarwal R, Katare OP, Kaur I, and Kumar B
- Subjects
- Adult, Double-Blind Method, Drug Compounding, Female, Humans, Male, Middle Aged, Ointments, Treatment Outcome, Anthralin therapeutic use, Dermatologic Agents therapeutic use, Liposomes, Psoriasis drug therapy
- Abstract
Dithranol is infrequently used in psoriasis in spite of excellent efficacy due to its local adverse effects. We have synthesized a novel formulation of dithranol in which the drug is entrapped in phospholipid liposomes. This formulation has shown markedly low irritation and minimal staining of skin and clothes in preliminary studies. Twenty patients with bilaterally symmetrical stable plaque psoriasis applied 0.5% dithranol lipogel to lesions over one side of the body. On the other side, 10 patients were randomized to apply pure liposomal base and 10 applied a conventional cream containing 1.15% dithranol, 1.15% salicylic acid and 5.3% coal tar in a 30-minute, short contact regimen for 6 weeks. Patients were assessed for disease severity, perilesional erythema and skin staining, pruritus and any other adverse effects at baseline, 2, 4 and 6 weeks. Both lipogel and the cream significantly reduced the total severity score compared to the liposomal base at 4 (p = 0.004) and 6 (p = 0.01) weeks. There was no significant difference in the clinical response of dithranol cream and lipogel. Markedly low incidence and severity of perilesional erythema (p<0.001) and skin staining (p<0.05) was seen with the lipogel in comparison with the cream.
- Published
- 2007
- Full Text
- View/download PDF
4. Co-localization of epidermal nevi and psoriasis:are we closer to an explanation?
- Author
-
Saraswat A, Jain R, Kaur I, and Kumar B
- Subjects
- Adult, Biopsy, Needle, Child, Follow-Up Studies, Humans, Immunohistochemistry, Male, Nevus, Pigmented complications, Nevus, Pigmented diagnosis, Psoriasis complications, Psoriasis diagnosis, Risk Assessment, Severity of Illness Index, Skin Neoplasms complications, Skin Neoplasms diagnosis, Nevus, Pigmented pathology, Psoriasis pathology, Skin Neoplasms pathology
- Published
- 2005
- Full Text
- View/download PDF
5. Potential therapeutic role of peroxisome proliferator activated receptor-gamma agonists in psoriasis.
- Author
-
Malhotra S, Bansal D, Shafiq N, Pandhi P, and Kumar B
- Subjects
- Animals, Anti-Inflammatory Agents pharmacology, Drug Evaluation, Preclinical, Homeostasis, Humans, PPAR gamma metabolism, Psoriasis etiology, Psoriasis metabolism, Randomized Controlled Trials as Topic, Risk Factors, Skin drug effects, Skin metabolism, Thiazolidinediones pharmacology, Anti-Inflammatory Agents therapeutic use, PPAR gamma agonists, Psoriasis drug therapy, Thiazolidinediones therapeutic use
- Abstract
Psoriasis is a chronic inflammatory condition affecting 1 - 3% of the world's population. Despite the availability of several agents, therapeutic options remain limited. With a better understanding of the pathophysiology of psoriasis, several potential therapeutic targets have been identified. Peroxisome proliferator activated receptors have been shown to play a role in cutaneous homeostasis. This review focuses on the potential therapeutic role of peroxisome proliferator activated receptor-gamma agonists in psoriasis and the possibility for the future prospects.
- Published
- 2005
- Full Text
- View/download PDF
6. Pilot trial: Pioglitazone versus placebo in patients with plaque psoriasis (the P6).
- Author
-
Shafiq N, Malhotra S, Pandhi P, Gupta M, Kumar B, and Sandhu K
- Subjects
- Adult, Aged, Double-Blind Method, Female, Humans, Male, Middle Aged, Pilot Projects, Pioglitazone, Prospective Studies, Psoriasis drug therapy, Thiazolidinediones therapeutic use
- Abstract
Background: Disordered differentiation and hyperproliferation of keratinocytes with inflammation are the hallmarks of psoriasis. Ligand activation of peroxisome proliferator receptor-gamma (a class of nuclear receptors) by thiazolidinediones can normalize the histologic features of psoriasis., Method: In a 10-week, double-blind, randomized, placebo-controlled, parallel-group study, 70 patients with moderate to severe psoriasis received one of the following treatments: pioglitazone 15 mg, pioglitazone 30 mg or placebo. Efficacy was evaluated by observing the change in the psoriasis area and severity index (PASI) after 10 weeks of treatment., Results: There was a dose-dependent improvement in psoriasis. Median PASI scores at the end of 10 weeks were significantly reduced in the pioglitazone treatment groups as compared to the placebo-treated group. The psoriasis lesions cleared in more than 40% of patients treated with pioglitazone as compared to 12.5% of those with placebo. The percentage reduction in mean PASI scores was 21.6%, 41.1% and 47.5% in the placebo, pioglitazone 15 mg, and 30 mg groups, respectively. No serious adverse events were detected., Conclusion: This is the first report from a controlled trial demonstrating that pioglitazone could be considered as an efficacious and safe agent for the treatment of plaque psoriasis. The optimum dose and duration of pioglitazone therapy remain to be determined.
- Published
- 2005
- Full Text
- View/download PDF
7. Topical 0.25% methotrexate gel in a hydrogel base for palmoplantar psoriasis.
- Author
-
Kumar B, Sandhu K, and Kaur I
- Subjects
- Administration, Topical, Adolescent, Adult, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Gels, Humans, Male, Middle Aged, Prospective Studies, Severity of Illness Index, Treatment Outcome, Methotrexate therapeutic use, Psoriasis diagnosis, Psoriasis drug therapy
- Abstract
Palmoplantar psoriasis (PPP) is a chronic, disfiguring condition, and its management is difficult. The systemic side effects of methotrexate can be avoided if it is effective topically. We studied the efficacy and safety of a recently marketed topical methotrexate (0.25%) preparation in a hydrogel base in patients with palmoplantar lesions. A total of 14 adult patients diagnosed clinically as plaque type of palmoplantar psoriasis (>30% of the palm and/or sole areas involved) were included in the study. Topical methotrexate 0.25% in a hydroxygel base was applied twice daily to the lesions for twelve weeks. The lesions were assessed for degree of erythema, scaling, induration and fissuring (ESIF) and were scored on a severity score of 0-3 (0--clear, 1--mild, 2--moderate, 3--severe) every two weeks. The most severe condition was given 12 points; 0 denoted no disease. The response at the end of the study was graded as minimal if there was up to 25% reduction in the EISF score, mild as 26-50% reduction, moderate improvement as 51-75% reduction in score, and marked improvement as >75% reduction in score. The average age of the 11 male and female patients was 41.5 years (18-57 years) with the duration of the disease varying from 2 months to 15 years. Ten patients had both palmar and plantar lesions; two each had only palmar lesions or plantar lesions. The ESI score at baseline was 5.8 +/- 0.9 for the palms and 6.8 +/- 0.5 for the soles. The scores at the end of the study were 3.5 +/- 0.7 for palms and 4.8 +/- 0.2 for the soles. The average time taken for improvement was at least six weeks. None of the patients had complete clearance of lesions. The drug was well tolerated by all patients. Methotrexate 0.25% in a hydrophilic gel is well tolerated but is not very effective in controlling the lesions of psoriasis on the palms and soles. A higher concentration in a different base with better penetration could possibly provide better results.
- Published
- 2004
- Full Text
- View/download PDF
8. Clostridium difficile toxin assay in psoriatic patients.
- Author
-
Kumar B, Vaishnavi C, Sandhu K, and Kaur I
- Subjects
- Adult, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Female, Humans, Immunosuppressive Agents therapeutic use, Male, Mesalamine therapeutic use, Methotrexate therapeutic use, Middle Aged, Psoriasis drug therapy, Bacterial Toxins analysis, Clostridioides difficile, Feces chemistry, Psoriasis microbiology
- Abstract
Chemotherapy-induced pseudomembranous colitis is most commonly associated with methotrexate and 5-fluorouracil. Methotrexate and mesalazine have also been used for the treatment of psoriasis but the effect of these therapies on the Clostridium difficile carriage in the stool of psoriatic patients has not been studied. Our aim was to detect the presence of C. difficile toxin in patients with psoriasis hospitalized for systemic therapy and in those receiving methotrexate and mesalazine. A total of 58 patients with psoriasis were divided into three groups: group A comprised 30 patients admitted with psoriasis involving >30% body surface area, group B1 comprised 15, psoriatic patients receiving methotrexate (0.3-0.4 mg/kg/week), group B2 included 6 patients receiving mesalazine (50-60 mg/kg/day) while group C comprised of 7 patients (5 on methotrexate, 2 on mesalazine) in whom stool samples were taken twice. Among patients in groups B1 and B2, stool samples were taken after at least 4 weeks of therapy. Detection of C. difficile toxin in stool samples was done using the latex agglutination method. Out of the 58 patients 47 were males and 11 were females. The mean age of the patients was 45+/-2.5 years and the duration of the disease was 3+/-0.9 years. Positive C. difficile toxin was found in a total of 19 patients in all three groups (5 patients in group A, 9 in group B1, 2 in group B2 and 3 in group C). Three patients complained of slight abdominal discomfort and increased frequency of stool, of whom 2 had toxin positive in low titres. The rest of the 17 patients who were positive for C. difficile toxin were asymptomatic. There is a obvious rise in the rate of GIT carriage of C. difficile to a variable degree in patients on methotrexate and mesalazine. However, no clear correlation of the gastrointestinal symptoms with either the presence of toxin or its titre could be established.
- Published
- 2004
9. Excessive drowsiness with low-dose methotrexate.
- Author
-
Handa S, Saraswat A, Kaur I, and Kumar B
- Subjects
- Diagnosis, Differential, Drug Administration Schedule, Female, Humans, Immunosuppressive Agents administration & dosage, Male, Methotrexate administration & dosage, Middle Aged, Immunosuppressive Agents adverse effects, Methotrexate adverse effects, Psoriasis drug therapy, Sleep Stages
- Published
- 2004
- Full Text
- View/download PDF
10. Epidemiology of childhood psoriasis: a study of 419 patients from northern India.
- Author
-
Kumar B, Jain R, Sandhu K, Kaur I, and Handa S
- Subjects
- Adolescent, Age Distribution, Child, Child Welfare, Child, Preschool, Female, Humans, India epidemiology, Infant, Male, Medical Records, Prevalence, Psoriasis etiology, Retrospective Studies, Psoriasis epidemiology
- Abstract
Background: We undertook this study in order to determine the pattern and prevalence of childhood psoriasis in northern India and to highlight the differences and similarities with previous studies., Materials and Methods: In this retrospective epidemiologic study, the data from 419 children (less than 14 years of age) with psoriasis registered at the Psoriasis Clinic between January 1990 and December 2002 were included., Results: The 419 children registered at the Psoriasis Clinic constituted 0.3% of the dermatology outpatients and 12.5% of the total psoriasis patients seen over a period of 13 years in the department. There were 219 (52.2%) boys and 200 (47.7%) girls, with a male to female ratio of 1.09 : 1. The age of onset ranged from 4 days to 14 years. The mean age of onset was 8.1 +/- 2.1 years in boys and 9.3 +/- 2.3 years in girls. The peak age of onset in boys was in the 6-10-year age group, whereas the majority of girls showed an onset of psoriasis between the ages of 10 and 14 years. A positive family history was present in only 19 (4.5%) patients. The extensors of the legs were the most common initial site affected [105 (25%) cases], followed by the scalp [87 (20.7%)]. Classical plaque psoriasis was the most frequent clinical presentation [254 (60.6%) patients], followed by plantar psoriasis [54 (12.8%)]. Nail involvement was observed in 130 (31%) cases. All types of nail changes described in psoriasis were seen in these patients. Pitting was the most common nail change, followed by ridging and discoloration. Five children (1.1%) (three girls and two boys) had psoriatic arthropathy. Precipitating factors that brought about the onset of the disease or were associated with exacerbation could be recalled in only 28 (6.6%) patients. Koebnerization was observed in 27.9% of patients. Pruritus was the most frequent symptom, reported by 365 (87.1%) children. Twenty-seven (6.4%) children had other concurrent mucocutaneous diseases (vitiligo, pityriasis alba, alopecia areata, ichthyosis vulgaris, halo nevus, aphthous stomatitis, urticaria, pityriasis versicolor, nummular eczema, salmon patch, and verrucous epidermal nevus). Eighteen children had systemic disorders, including seizures, bronchial asthma, mitral regurgitation, scleroderma, Down's syndrome, high arched palate, cholelithiasis, anterior mongoloid slant, and prognathism; however, these conditions were possibly chance findings only and no correlation with the age of onset or severity of the disease was found., Conclusions: Our findings differ from those of previous studies in showing a delayed onset, equal sex distribution, less frequent facial involvement, uncommon guttate lesions, more frequent involvement of the soles, and a less frequent history of familial occurrence.
- Published
- 2004
- Full Text
- View/download PDF
11. Cyclosporine in severe psoriasis: an Indian experience.
- Author
-
Kumar B, Sandhu K, and Kaur I
- Subjects
- Adult, Female, Humans, India, Male, Middle Aged, Prospective Studies, Treatment Outcome, Cyclosporine therapeutic use, Dermatologic Agents therapeutic use, Psoriasis drug therapy
- Published
- 2004
- Full Text
- View/download PDF
12. Localized hypertrichosis in subsiding psoriatic plaques.
- Author
-
Kumar B, Sandhu K, and Kaur I
- Subjects
- Adult, Arm, Diagnosis, Differential, Humans, Hypertrichosis complications, Hypertrichosis pathology, Leg, Male, Middle Aged, Psoriasis pathology, Hypertrichosis diagnosis, Psoriasis complications
- Published
- 2004
- Full Text
- View/download PDF
13. Psoriasis and vitiligo.
- Author
-
Sandhu K, Kaur I, and Kumar B
- Subjects
- Adolescent, Adult, Age of Onset, Aged, Aged, 80 and over, Child, Female, Humans, India, Male, Middle Aged, Retrospective Studies, Psoriasis complications, Vitiligo complications
- Published
- 2004
- Full Text
- View/download PDF
14. Leprosy and psoriasis: an enigmatic relationship.
- Author
-
Dogra S, Kaur I, and Kumar B
- Subjects
- Humans, Leprosy, Borderline etiology, Leprosy, Borderline pathology, Male, Middle Aged, Psoriasis etiology, Psoriasis pathology, Leprosy, Borderline complications, Psoriasis complications
- Abstract
The relationship between leprosy and psoriasis has been controversial since ancient times. Based on the fundamental importance of nerve involvement in the pathogenesis of leprosy and psoriasis, it has been hypothesized that leprosy patients may be protected from developing psoriasis. There are only sporadic reports of coexistence of these two diseases as evidence of this negative association. We report a 64-year-old male patient with borderline leprosy and psoriasis. Recent advances in the elucidation of pathogenesis of both diseases have contributed to the understanding of this enigmatic relationship. Various genetic, immunological, and structural alterations in leprosy and psoriasis as discussed could be responsible for the rare co-existence of these two diseases in a given patient.
- Published
- 2003
- Full Text
- View/download PDF
15. Calcipotriol versus coal tar: a prospective randomized study in stable plaque psoriasis.
- Author
-
Sharma V, Kaur I, and Kumar B
- Subjects
- Administration, Topical, Adolescent, Adult, Drug Administration Schedule, Esthetics, Female, Humans, Male, Middle Aged, Ointment Bases, Patient Satisfaction, Prospective Studies, Recurrence, Severity of Illness Index, Time Factors, Treatment Outcome, Calcitriol analogs & derivatives, Calcitriol therapeutic use, Coal Tar therapeutic use, Dermatologic Agents therapeutic use, Keratolytic Agents therapeutic use, Psoriasis drug therapy
- Abstract
Background: Topical therapies are the first line of treatment for patients with stable plaque psoriasis (SPP) affecting a limited body surface area. Very few trials comparing newer agents, such as 0.005% topical calcipotriol, with conventional modes of therapy, such as coal tar ointment, have been reported., Methods: A prospective, right-left randomized, investigator-blinded study with a 12-week treatment period and an 8-week follow-up period was performed. Thirty-six patients with nearly bilaterally symmetrical SPP lesions on the limbs were instructed to apply 5% coal tar ointment overnight on one side once daily and 0.005% calcipotriol ointment on the other side twice a day. All patients were advised to expose both sides to the sun for 2 h every day. Psoriatic lesions and progress during treatment were evaluated using the severity (0-3) scale of erythema, scaling and induration (ESI score). Evaluation was carried out every 2 weeks during the treatment period and monthly during follow-up. At the end of 12 weeks, patients with > 75% reduction in the ESI score were considered to be markedly improved, those with 51-75% reduction to be moderately improved, those with 26-50% reduction to be minimally improved and those with < 25% to be non-responders. Self-assessment by the patients regarding the efficacy and acceptability of the two modalities was on a five-point scale. Serum calcium, serum phosphate, total and differential serum proteins, 24-h urinary calcium and phosphate were monitored both at baseline and after completion of therapy., Results: Thirty of the 36 recruited patients completed the study. The difference in clinical response between the two sides was statistically significant at 4, 6 and 8 weeks, with the percentage reduction in ESI score with calcipotriol being 65.7 +/- 12.2% compared with 45.8 +/- 16.6% with coal tar at 8 weeks (P < 0.01, t = 6.4). However, the difference in clinical response at 10 and 12 weeks between the two sides was not significant, with a mean reduction of 71.9 +/- 13.3% in ESI score on the calcipotriol-treated side compared with 69.4 +/- 15.4% with coal tar ointment (P > 0.05). In the follow-up period of 8 weeks, recurrence of lesions was noted in 10% of patients treated with calcipotriol compared with 16.7% in those treated with coal tar after an average period of 6 +/- 1.2 and 5 +/- 1.3 weeks, respectively (P > 0.05)., Conclusions: It was found that 0.005% calcipotriol ointment produced a faster initial response and had better cosmetic acceptability in patients, although after a long period of treatment, i.e. 12 weeks, 5% coal tar ointment had comparable efficacy. There was no statistically significant difference in the relapse rates between the two modalities.
- Published
- 2003
- Full Text
- View/download PDF
16. Efficacy and safety of cyclosporine versus methotrexate in severe psoriasis: a study from north India.
- Author
-
Sandhu K, Kaur I, Kumar B, and Saraswat A
- Subjects
- Adult, Cyclosporine administration & dosage, Cyclosporine adverse effects, Dermatologic Agents administration & dosage, Dermatologic Agents adverse effects, Drug Administration Schedule, Female, Humans, India, Male, Methotrexate administration & dosage, Methotrexate adverse effects, Middle Aged, Prospective Studies, Treatment Outcome, Cyclosporine therapeutic use, Dermatologic Agents therapeutic use, Methotrexate therapeutic use, Psoriasis drug therapy
- Abstract
Treatment of patients with severe psoriasis is difficult. Among the number of systemic drugs that are available, methotrexate has long been used, but cyclosporine has been recently recommended for the management of severe psoriasis. The purpose of this study was to compare the efficacy and safety of daily cyclosporine with weekly methotrexate in the management of severe psoriasis. Thirty consecutive patients with severe psoriasis were randomly assigned to treatment with cyclosporine or methotrexate. The initial dose of cyclosporine was 3 mg/kg/day, which was increased to a maximum of 4 mg/kg after two weeks of therapy when the response was not adequate. Methotrexate was administered weekly at a dose of 0.5 mg/kg. Clinical response was assessed by calculating PASI score in all patients at biweekly intervals. Patients were followed up fortnightly up to a maximum of 12 weeks. The doses of both drugs were gradually tapered once >75% reduction in disease severity was attained. Marked improvement (>75%) reduction in PASI was noted in all patients except for one in the cyclosporine group. The median time for marked improvement was 5.3 weeks with methotrexate and 6.8 weeks with cyclosporine. Patients on methotrexate were found to have more rapid and complete clearance than those on cyclosporine. Both drugs were well tolerated. Side effects in both the treatment groups were minor, transient, and manageable. At doses with comparable safety profiles, methotrexate resulted in more rapid and cost effective clearance of patients with severe psoriasis. Cyclosporine can provide an effective and safe alternative.
- Published
- 2003
- Full Text
- View/download PDF
17. Role of Pityrosporum ovale in guttate psoriasis.
- Author
-
Sandhu K, Jain R, Kaur I, and Kumar B
- Subjects
- Aged, Antifungal Agents administration & dosage, Biopsy, Needle, Chronic Disease, Dermatomycoses complications, Dermatomycoses diagnosis, Dermatomycoses drug therapy, Fluconazole administration & dosage, Follow-Up Studies, Humans, Immunohistochemistry, Lower Extremity, Malassezia drug effects, Male, Psoriasis complications, Psoriasis diagnosis, Risk Assessment, Severity of Illness Index, Treatment Outcome, Dermatomycoses pathology, Malassezia isolation & purification, Psoriasis pathology
- Published
- 2003
- Full Text
- View/download PDF
18. A novelliposomal formulation of dithranol for psoriasis: preliminary results.
- Author
-
Agarwal R, Saraswat A, Kaur I, Katare OP, and Kumar B
- Subjects
- Administration, Topical, Anthralin adverse effects, Anti-Inflammatory Agents adverse effects, Drug Carriers, Female, Humans, Liposomes, Male, Prospective Studies, Anthralin administration & dosage, Anti-Inflammatory Agents administration & dosage, Psoriasis drug therapy
- Abstract
We have prepared a novel, aqueous gel-based, liposome-entrapped formulation of dithranol. Herein, we report preliminary observations on its efficacy, tolerability, and cosmetic acceptability in treating stable plaque psoriasis. Nineteen plaques of psoriasis in nine adult patients were treated for six weeks in a prospective, open-label trial. In five patients, there was total clearance of lesions, with more than 50% subsidence in a further two patients. Significantly, there were no reports of lesional or perilesional irritation, and only one patient showed faint brown staining of the skin, which was completely and rapidly reversible. These preliminary results indicate that our liposomal dithranol gel has potential advantages over presently available preparations of dithranol; these may translate into enhanced acceptance of this useful drug by patients and physicians.
- Published
- 2002
- Full Text
- View/download PDF
19. Short-term methotrexate therapy in psoriasis: a study of 197 patients.
- Author
-
Kumar B, Saraswat A, and Kaur I
- Subjects
- Adolescent, Adult, Aged, Child, Child, Preschool, Dermatologic Agents administration & dosage, Female, Humans, Liver Diseases pathology, Liver Diseases physiopathology, Male, Methotrexate administration & dosage, Middle Aged, Outcome Assessment, Health Care, Psoriasis pathology, Psoriasis physiopathology, Retrospective Studies, Severity of Illness Index, Time Factors, Chemical and Drug Induced Liver Injury, Dermatologic Agents adverse effects, Dermatologic Agents therapeutic use, Methotrexate adverse effects, Methotrexate therapeutic use, Psoriasis drug therapy
- Abstract
Methotrexate (MTX) is one of the most effective antipsoriatic drugs available. Although it is undeniably hepatotoxic, it can be used safely in most patients with severe psoriasis if established guidelines are followed. Current opinion on the monitoring of hepatic damage is divided, however, and the need for repeated liver biopsies during MTX therapy is being re-examined. We have used MTX in a short-term protocol in our patients with psoriasis for the past 20 years, and have recently attempted to minimize or eliminate the need for liver biopsies using this regimen. Data on 244 psoriatics who were given MTX from 1981 to 2000 have been reviewed. Our protocol entailed the use of weekly oral MTX at the full therapeutic dose during episodes of peak disease activity, with tapering off of MTX when the disease subsided in response to treatment combined with natural/seasonal remission. Intensive topical and heliotherapy were encouraged throughout to facilitate the earliest possible drug withdrawal and the longest possible drug-free interval before the next relapse. Strict inclusion criteria were applied before starting MTX. A total of 243 cycles of MTX therapy have been given to 197 evaluable patients. More than 75% improvement occurred in 88% of patients in 8.5 +/- 5.1 weeks. The mean cumulative dose was 709.3 +/- 369.2 mg and the mean duration of follow-up was 16.5 +/- 9.1 months. Fifteen (6.1%) patients had serious adverse effects requiring the cessation of therapy. Only three patients had deranged liver function tests. Thirty-four pre-MTX and 13 post-MTX liver biopsies were taken, which revealed grade I or II changes that were nonprogressive. Our experience with short-term MTX therapy has enabled us to safely administer MTX to our patients with minimal recourse to liver biopsy. In developing countries, where advanced noninvasive methods for the assessment of liver damage are unaffordable or unavailable, this interrupted, short-term regimen may present an acceptable and safe method of using MTX in carefully selected patients with severe psoriasis.
- Published
- 2002
- Full Text
- View/download PDF
20. Acropigmentation of Dohi in an Indian family.
- Author
-
Dogra S, Saraswat A, Rai R, and Kumar B
- Subjects
- Child, Humans, Male, Pedigree, Pigmentation Disorders genetics, Pigmentation Disorders complications, Psoriasis complications
- Published
- 2002
- Full Text
- View/download PDF
21. Palmoplantar lesions in psoriasis: a study of 3065 patients.
- Author
-
Kumar B, Saraswat A, and Kaur I
- Subjects
- Adolescent, Adult, Aged, Child, Epidemiologic Studies, Female, Humans, India epidemiology, Keratoderma, Palmoplantar epidemiology, Keratoderma, Palmoplantar pathology, Male, Middle Aged, Prevalence, Psoriasis epidemiology, Psoriasis pathology, Keratoderma, Palmoplantar complications, Psoriasis complications
- Abstract
Although palmoplantar psoriasis can be severely disabling, there are very few large clinico-epidemiological studies on this condition. Our purpose was to study the morphology and pattern of lesions in Indian patients with palmoplantar psoriasis and to elucidate the role of occupation in the incidence/localization of these lesions. All patients attending our Psoriasis Clinic from 1993 to 2000 were screened for palmoplantar lesions and their demographic characteristics, occupation and the exact localization of the lesions were noted. Out of 3,065 patients screened, 532 had palm and/or sole involvement. Plantar lesions were seen in 91.9% and palmar lesions in 55.6% of these patients. Four distinct patterns of lesion localization were noted on the palms and 5 patterns on the soles. Almost half of the men involved in regular manual labor had palmar lesions restricted to areas exposed to pressure, whereas only a quarter of other men had this type of lesion pattern. All patients with unilateral palmar lesions had them on their dominant hand and these patients were involved in regular manual labor. In our patients, the prevalence of plantar lesions was much higher than that of palmar lesions. The possible role of occupational trauma in lesion localization in Indian patients with palmoplantar psoriasis is discussed.
- Published
- 2002
- Full Text
- View/download PDF
22. Frequency of patch-test positivity in patients with psoriasis: a prospective controlled study.
- Author
-
Malhotra V, Kaur I, Saraswat A, and Kumar B
- Subjects
- Adult, Allergens adverse effects, Case-Control Studies, Dermatitis, Allergic Contact etiology, Female, Humans, Male, Patch Tests statistics & numerical data, Prospective Studies, Dermatitis, Allergic Contact diagnosis, Patch Tests methods, Psoriasis complications
- Abstract
Current information on the incidence of patch-test positivity and the spectrum of allergens in psoriatics is conflicting. We compared the rates of patch-test positivity to common allergens and topical medicaments in 200 patients suffering from chronic plaque psoriasis (group I) with 51 patients with other non-allergic skin complaints (group II) and 54 patients suspected of having allergic contact dermatitis (group III). Positive patch-test results to one or more allergens were detected in 21.6% of patients in group I, 23.5% in group II and 50.0% in group III. Psoriatics with > or = 5 years old disease had a higher rate of patch-test positivity than those with shorter disease duration (p<0.01). The site of lesions showed no correlation with patch-test positivity. The commonest allergens showing positivity in group I were dithranol (6.5%), nickel (6%), fragrance mix (5%), neomycin (2%) and nitrofurazone (2%). In spite of the comparable rates of patch-test positivity in psoriatics and general dermatology outpatients, the predominance of sensitivity to topical medicaments and fragrance in the former group was striking. A separate psoriasis series focusing on topical agents may give more accurate information on this subject.
- Published
- 2002
- Full Text
- View/download PDF
23. The coexistence of photosensitive psoriasis with chronic actinic dermatitis.
- Author
-
Sahoo B and Kumar B
- Subjects
- Chronic Disease, Follow-Up Studies, Humans, India, Male, Middle Aged, Photosensitivity Disorders diagnosis, Psoriasis diagnosis, Photosensitivity Disorders complications, Psoriasis complications
- Abstract
A 57-year-old-male who had been a known case of psoriasis vulgaris for 30 years had a history of summer exacerbation of the disease. Subsequently in the course of the disease process, he developed lesions of chronic actinic dermatitis (CAD) on the face and dorsum of both hands. The association of CAD with photosensitive psoriasis is very rare. Only one case report is known till now. It may suggest that there is a relationship between the two diseases., (Copyright 2002 S. Karger AG, Basel)
- Published
- 2002
- Full Text
- View/download PDF
24. Clinical trial Calcipotriol versus coal tar: a prospective randomized study in stable plaque psoriasis.
- Author
-
Sharma, Vikas, Kaur, Inderjeet, and Kumar, Bhushan
- Subjects
PSORIASIS ,COAL tar ,OINTMENTS ,ERYTHEMA - Abstract
Topical therapies are the first line of treatment for patients with stable plaque psoriasis (SPP) affecting a limited body surface area. Very few trials comparing newer agents, such as 0.005% topical calcipotriol, with conventional modes of therapy, such as coal tar ointment, have been reported. A prospective, right–left randomized, investigator-blinded study with a 12-week treatment period and an 8-week follow-up period was performed. Thirty-six patients with nearly bilaterally symmetrical SPP lesions on the limbs were instructed to apply 5% coal tar ointment overnight on one side once daily and 0.005% calcipotriol ointment on the other side twice a day. All patients were advised to expose both sides to the sun for 2 h every day. Psoriatic lesions and progress during treatment were evaluated using the severity (0–3) scale of erythema, scaling and induration (ESI score). Evaluation was carried out every 2 weeks during the treatment period and monthly during follow-up. At the end of 12 weeks, patients with > 75% reduction in the ESI score were considered to be markedly improved, those with 51–75% reduction to be moderately improved, those with 26–50% reduction to be minimally improved and those with < 25% to be non-responders. Self-assessment by the patients regarding the efficacy and acceptability of the two modalities was on a five-point scale. Serum calcium, serum phosphate, total and differential serum proteins, 24-h urinary calcium and phosphate were monitored both at baseline and after completion of therapy. Thirty of the 36 recruited patients completed the study. The difference in clinical response between the two sides was statistically significant at 4, 6 and 8 weeks, with the percentage reduction in ESI score with calcipotriol being 65.7 ± 12.2% compared with 45.8 ± 16.6% with coal tar at 8 weeks ( P < 0.01, t = 6.4). However, the difference in clinical response at 10 and 12 weeks between the two sides was not significant, with a mean reduction of 71.9 ± 13.3% in ESI score on the calcipotriol-treated side compared with 69.4 ± 15.4% with coal tar ointment ( P > 0.05). In the follow-up period of 8 weeks, recurrence of lesions was noted in 10% of patients treated with calcipotriol compared with 16.7% in those treated with coal tar after an average period of 6 ± 1.2 and 5 ± 1.3 weeks, respectively ( P > 0.05). It was found that 0.005% calcipotriol ointment produced a faster initial response and had better cosmetic acceptability in patients, although after a long period of treatment, i.e. 12 weeks, 5% coal tar ointment had comparable efficacy. There was no statistically significant difference in the relapse rates between the two modalities. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
25. Marginal acrokeratoderma and psoriasis: is there an association?
- Author
-
Rai, Ranju, Saraswat, Abir, Kaur, Inderjeet, and Kumar, Bhushan
- Subjects
PSORIASIS ,CUTANEOUS manifestations of general diseases ,SYMPTOMS - Abstract
Case 1 A 70-year-old housewife presented to us with multiple, asymptomatic, depressed, crateriform plaque lesions over the radial margin of the index finger and thumb and thenar and hypothenar eminences of both hands of 25 years' duration (Fig. 1). There was no history of prolonged sun exposure or repeated trauma to the hands and there were no such lesions on the soles. None of her other family members were affected. We made a provisional diagnosis of keratoelastoidosis marginalis. Skin biopsy revealed an unremarkable epidermis, with minimal lymphocytic infiltration in the upper dermis and hyalinization in the reticular dermis, extending to the deeper dermis. Two years later she returned with well-defined, erythematous, scaly, mildly itchy plaque lesions over the instep of both feet and the center of both palms. A clinical diagnosis of palmoplantar psoriasis was made. [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
26. Coal tar therapy in palmoplantar psoriasis: old wine in an old bottle?
- Author
-
Kumar, Bhushan, Kumar, Ravi, and Kaur, Inderjeet
- Subjects
PSORIASIS ,THERAPEUTICS ,PETROLATUM ,SALICYLIC acid ,OINTMENTS ,SKIN diseases - Abstract
Background Palmoplantar psoriasis (PPP) is a disabling condition which is usually resistant to most of the available therapeutic modalities. Coal tar is an accepted therapy for psoriasis which has not been well studied for PPP. Methods Thirty patients with a plaque type of PPP were allocated into two groups: Group A (19 patients) were treated with 6% crude coal tar (COT) ointment and Group B (11 patients) were treated with white petrolatum and salicylic acid. In both groups, ointment was applied and left on overnight. Wearing of gloves and socks during the night and application of emollients in the day was routinely advised The lesions were assessed for erythema, scaling, and induration (ESI) every 2 weeks for a total of 8 weeks. Patients with greater than 50% improvement were considered to have good improvement. Side-effects, if any, were also monitored. Results In Group A, 76.5% of patients (13/17) showed good improvement, whereas only 45.5% of patients (5/11) in Group B showed the same magnitude of improvement (P < 0.05). No side-effects were reported by any patient in either of the groups. Conclusions Crude coal tar is a safe, effective, and inexpensive modality for the treatment of PPP. We recommend coal tar under occlusion, along with the liberal use of emollients, as the first line of therapy for all cases of PPP. [ABSTRACT FROM AUTHOR]
- Published
- 1997
- Full Text
- View/download PDF
27. THE RARE COEXISTENCE OF LEPROSY AND PSORIASIS.
- Author
-
Kumar, Bhushan, Raychaudhuri, S. P., Vossough, Slavosh, and Farber, Eugene M.
- Subjects
PSORIASIS ,HANSEN'S disease ,SKIN diseases ,EPIDEMIOLOGY ,IMMUNE response ,IMMUNOLOGY ,NEUROPEPTIDES - Abstract
The article presents information on the study which examines whether the incidence of psoriasis is less in leprosy patients. Leprosy is characterized by peripheral nerve damage. Findings demonstrates rare co-existence of the two diseases, although a few cases had clinical signs for both leprosy and psoriasis. The rarity of psoriasis in leprosy patients is due to first, altered immune response and secondly differences in genetic makeup. The release of neuropeptides is possibly responsible for triggering psoriasis.
- Published
- 1992
- Full Text
- View/download PDF
28. Nail changes in psoriasis: a study of 167 patients.
- Author
-
Kaur, Inderjeet, Saraswat, Abir, and Kumar, Bhushan
- Subjects
NAIL diseases ,PSORIASIS ,PATIENTS - Abstract
Examines the frequency of various nail changes in patients with psoriasis in Chandigarh, India. Diagnosis of psoriasis; Description of individual nail changes; Comparison of mean number of nail changes per subject with nail fold involvement; Types of nail changes caused by psoriasis.
- Published
- 2001
- Full Text
- View/download PDF
29. Methotrexate in Childhood Psoriasis.
- Author
-
Kumar, Bhushan, Dhar, Sandipan, Handa, Sanjeev, and Kaur, Inderjeet
- Subjects
PSORIASIS ,JUVENILE diseases ,METHOTREXATE ,PATIENTS ,BIOPSY ,NAUSEA - Abstract
We treated childhood psoriasis with methotrexate (MTX) in seven children (4 boys, 3 girls) over 7.5 years. Their ages and duration of disease varied from 3.5 to 16 years (mean 12.14 yrs) and 4.8 months to 5 years (mean 2.2 yrs), respectively. Psoriatic erythroderma was seen in three patients, generalized pustular psoriasis in two, recalcitrant psoriasis and psoriatic arthropathy in one each. Pre-MTX liver biopsy performed in 4 children showed grade I changes. Methotrexate was given in a single weekly oral dose of 3.75 to 25 mg (mean 16.6 mg). The duration of treatment necessary to control the disease varied from 6 to 10 weeks (mean 7.9 wks). Total duration of MTX therapy was 31.2 to 46.4 weeks (mean 38.8 wks). Posttherapy disease-free interval ranged between 14.4 and 16.8 weeks (mean 15.5 wks). Follow-up after withdrawal of MTX was 16 to 28 weeks (mean 22.3 wks). Total cumulative MTX dose ranged from 390 to 960 mg (mean 683.6 mg). Side effects were nausea and vomiting in three patients. [ABSTRACT FROM AUTHOR]
- Published
- 1994
- Full Text
- View/download PDF
30. Childhood Psoriasis: An Epidemiologic Survey of 112 Patients.
- Author
-
Nanda, Arti, Kaur, Surrinder, Kaur, Inderjeet, and Kumar, Bhushan
- Subjects
SKIN diseases ,DERMATOLOGY ,BEHCET'S disease ,PSORIASIS ,PSORIATIC arthritis ,EPIDEMIOLOGY - Abstract
One hundred and twelve cases of childhood psoriasis, constituting 5% of all psoriasis patients registered in our clinic, were studied over a period of nine years (January 1980 to December 1988). There were 57 male and 55 female patients. Age of onset ranged from 1 month to 13 years, with a mean and median age of 7 years. A positive family history of psoriasis was elicited from 9.8% of patients. The commonest form of psoriasis found was plaque (89.6%), followed by guttate (25.9%). infection was the most common triggering factor, occurring in 15.2% of cases. Many of these findings are at variance with observations reported elsewhere for this age group. [ABSTRACT FROM AUTHOR]
- Published
- 1990
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.